A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 22 Jan 2016 Primary endpoint of percentage of North American patients achieving PASI-75 at week 12 has been met, according to results published in the British Journal of Dermatology.
    • 22 Jan 2016 Results published in the British Journal of Dermatology
    • 07 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top